The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration
Abstract
The extracellular matrix is a significant barrier to the effective subcutaneous delivery of many drugs, limiting both pharmacokinetic parameters and injection volumes. The space outside adipocytes in the hypodermis is not a fluid, but rather a solid extracellular matrix of collageneous fibrils embedded within a glycosaminoglycan-rich viscoelastic gel that buffers convective forces. The extracellular matrix limits the volume of drug that can be injected at a single site, as well as the rate and amount that reach the vascular compartment. A fully human recombinant DNA-derived hyaluronidase enzyme (rHuPH20) has been developed to leverage the historical efficacy of animal testes extract-derived spreading factors to reversibly modify the hypodermis, in light of discovery of the human hyaluronidase gene family. The application of this technology to increase both injection volumes and bioavailability from subcutaneous injection may overcome some key limitations of this route of administration in multiple settings of care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it has been shown that coadministration of the dispersion enhancer hyaluronidase facilitates spreading of an injected volume in the subcutaneous interstitial space and, therefore, enables injection of a larger volume at an individualized rate at the patient’s preferred injection site (e.g. thigh, abdomen, or upper arm) [18].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [18]
In the citing paper
“Hyaluronan provides a barrier against the spreading of injected fluids [18].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [18]
In the citing paper
“Intravenous doses from 38 to 12,000 units/kg in rhesus primates and 10,500 units/kg in rodents have been generally well-tolerated.”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [18]
In the citing paper
“In primates, rHuPH20 has been shown to be well-tolerated at 45,000 units per subcutaneous injection and 4500 units per periocular injection.”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [18]
In the citing paper
“In an attempt to increase the subcutaneous bioavailability of a biotherapeutic, subcutaneous infusions can be coadministered (or produced as coformulations) with the dispersion-enhancer hyaluronidase (discussed in detail in Sect. 4), an enzyme that facilitates spreading of an injected fluid in the subcutaneous tissue [18].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [18]
Citations
Cites
On the Absorption of Fluids from the Connective Tissue Spaces
Starling, E. H. (1896) · The Journal of Physiology · doi:10.1113/jphysiol.1896.sp000596 · Cited by 2,126
Cell Biology of Extracellular Matrix
Hay, E. D. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0881-2 · Cited by 1,470
Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products
Verzijl, N., DeGroot, J., Thorpe, S. R., Bank, R. A., Shaw, J., Lyons, T. J., Bijlsma, J. W. J., Lafeber, F. P. J. G., Baynes, J., & TeKoppele, J. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006700200 · Cited by 979
Interstitial-lymphatic mechanisms in the control of extracellular fluid volume
Aukland, K., & Reed, R. K. (1993) · Physiological Reviews · doi:10.1152/physrev.1993.73.1.1 · Cited by 938
The six hyaluronidase-like genes in the human and mouse genomes
Csoka, A. B., Frost, G. I., & Stern, R. (2001) · Matrix Biology · doi:10.1016/s0945-053x(01)00172-x · Cited by 590
Self-citationLundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Supersaxo, A., Hein, W. R., & Steffen, H. (1990) · Pharmaceutical Research · doi:10.1023/a:1015880819328 · Cited by 386
A recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282
Self-citationPurification, Cloning, and Expression of Human Plasma Hyaluronidase
Frost, G. I., Csóka, T. B., Wong, T., & Stern, R. S. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6773 · Cited by 236
Self-citationBee venom hyaluronidase is homologous to a membrane protein of mammalian sperm.
Gmachl, M., & Kreil, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3569 · Cited by 206
Flagged first, then by citations
Research works printed but not linked: 18
- TAYLOR, 1984, Am. Physiol. Soc., 4, 467
- REED, 1989, Am. J. Physiol., 257, 1819
- FRASER, 1989, Ciba Found. Symp., 143, 41
- MCMINN RMH (Ed.), Last's Anatomy: Regional and applied (9th Edition). London: Churchill Livingstone (1994).
- 10.1113/expphysiol.1991.sp003536 · DOI
- DURAN, 1928, Comptes Rendus Hebdomadaires de Séances et Mémoires de la Société de Biologie, 99, 6
- DUTHIE, 1939, Nature, 977
- MEYER K, Hyaluronidases, In : BOYER PD (Ed.), The Enzymes. Academic Press, New York, (1971):307-320.
- MEYER, 1952, Adv. Enzymol. Relat. Subj. Biochem., 13, 199
- MEYER K, HOFFMAN P, LINKER A: HYALURONIDASES. In: BOYER PD, LARDY H, MYRBÄCK K (Eds), The Enzymes, 2nd Edition, Volume 4, Academic Press, New York (1960):447-460.
- HYUGA, 1993, Int. J. Dev. Biol., 37, 319
- LINSENMAYER, 1981, Plenum, 5
- WOLF, 1982, J. Pharmacol. Exp. Ther., 222, 331
- JAWORSKI, 1950, Am. J. Dis. Child., 79, 59
- ALWITRY, 2002, J. Cataract Refract. Surg., 8, 11420
- 1998, J. Intravenous Nursing, 21, S36
- RASZKA, 1990, J. Perinatol., 10, 146
- SIMON, 1949, Amer. J. Roentgen., 61, 91
Cited by
Sorted by citations
Items 101–200 of 323
Muchmore, D. B., & Vaughn, D. E. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600405 · Cited by 37
The role of glycans in the mechanobiology of cancer
Purushothaman, A., Mohajeri, M., & Lele, T. P. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.102935 · Cited by 36
Fathallah, A. M., & Balu‐Iyer, S. V. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24277 · Cited by 35
Focus on therapeutic peptides and their delivery
Rosson, E., Lux, F., David, L., Godfrin, Y., Tillement, O., & Thomas, E. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125555 · Cited by 36
Zheng, F., Hou, P., Corpstein, C. D., Xing, L., & Li, T. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03032-w · Cited by 35
Bittner, B., Richter, W., Hourcade-Potelleret, F., Herting, F., & Schmidt, J. (2014) · Drug Research · doi:10.1055/s-0033-1363993 · Cited by 32
Characterization of a Novel Recombinant Hyaluronan Binding Protein for Tissue Hyaluronan Detection
Jadin, L., Huang, L., Wei, G., Zhao, Q., Gelb, A. B., Frost, G. I., Jiang, P., & Shepard, H. M. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414540176 · Cited by 32
Self-citationBordat, A., Boissenot, T., Ibrahim, N., Ferrere, M., Levêque, M., Potiron, L., Denis, S., Garcia‐Argote, S., Carvalho, O., Abadie, J., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c04944 · Cited by 32
Freyer, G., Bakrin, Hamizi, Hénin, É., Mohtaram, Saux, O. L., & Falandry, C. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s27733 · Cited by 30
Morrow, L., Muchmore, D. B., Ludington, E. A., Vaughn, D. E., & Hompesch, M. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0115 · Cited by 30
Violette, A., Leonardi, A., Piquemal, D., Terrat, Y., Biass, D., Dutertre, S., Noguier, F., Ducancel, F., Stöcklin, R., Križaj, I., et al. (2012) · Marine Drugs · doi:10.3390/md10020258 · Cited by 30
Spandorfer, P. R. (2011) · Pediatric Emergency Care · doi:10.1097/pec.0b013e31820e1405 · Cited by 29
Hou, P., Zheng, F., Corpstein, C. D., Xing, L., & Li, T. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03062-4 · Cited by 29
HYAL-2–WWOX–SMAD4 Signaling in Cell Death and Anticancer Response
Hsu, L., Chiang, M., Sze, C., Su, W.-P., Yap, Y. V., Lee, I.-T., Kuo, H., & Chang, N. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00141 · Cited by 30
Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
Jolles, S. R. A. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31136 · Cited by 28
Subcutaneous fluid and drug delivery: safe, efficient and inexpensive
Noriega, Ó. D., & Ariño‐Blasco, S. (2015) · Reviews in Clinical Gerontology · doi:10.1017/s095925981500012x · Cited by 28
Kang, D. W., Jadin, L., Nekoroski, T., Drake, F. H., & Zepeda, M. L. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0065-3 · Cited by 27
Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
Alsina, L., Ronsano, J. B. M., Moral, P. M., Neth, O., Ortiz-Pica, M., Sánchez‐Ramón, S., Presa, M., Oyagüez, I., Casado, M. Á., & González‐Granado, L. I. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01378-x · Cited by 27
Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology
Jacquot, G., Navarro, P. L., Grange, C., Boudali, L., Harlepp, S., Pivot, X. B., & Detappe, A. (2024) · Advanced Materials · doi:10.1002/adma.202406604 · Cited by 26
Styles, I. K., Feeney, O. M., Nguyen, T., Brundel, D. H. S., Kang, D. W., Clift, R., McIntosh, M. P., & Porter, C. J. H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.040 · Cited by 26
Dolton, M. J., Chesterman, A., Moein, A., Sink, K. M., Waitz, A., Blondeau, K., Kerchner, G. A., Hu, N., Brooks, L., Wetzel-Smith, M. K., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2385 · Cited by 27
Rahimi, E., Gómez, H., & Ardekani, A. M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122125 · Cited by 26
村山, 重., 山田, 秀., Haller, M. F., & Flament, J. (2009) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.03.010 · Cited by 26
Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein
Kang, D. W., Oh, D. A., Fu, G., Anderson, J. M., & Zepeda, M. L. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.01.011 · Cited by 26
Hompesch, M., Muchmore, D. B., Morrow, L., Ludington, E., & Vaughn, D. E. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0117 · Cited by 25
Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion
Mihajlović, J., Bax, P., van Breugel, E., Blommestein, H. M., Hoogendoorn, M., Hospes, W., & Postma, M. J. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.342 · Cited by 25
Printz, M. A., Dychter, S. S., DeNoia, E. P., Harrigan, R., Sugarman, B. J., Zepeda, M. L., Souratha, J., Kang, D. W., & Maneval, D. C. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100604 · Cited by 25
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Struble, E. B., Rawson, J. M. O., Stantchev, T. S., Scott, D., & Shapiro, M. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051538 · Cited by 27
Clement, H. C., Olvera, A., Rodríguez, M., Zamudio, F. Z., Palomares, L. A., Possani, L. D., Odell, G. V., Alagón, A., & Sánchez‐López, R. (2012) · Toxicon · doi:10.1016/j.toxicon.2012.08.018 · Cited by 25
Modern management of primary B‐cell immunodeficiencies
Hoernes, M., Seger, R. A., & Reichenbach, J. (2011) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2011.01236.x · Cited by 25
Messina, L., Gavira, J. A., Pernagallo, S., Unciti-Broceta, J. D., Sanchez-Martin, R. M., Díaz‐Mochon, J. J., Vaccaro, S., Conejero‐Muriel, M., Pineda‐Molina, E., Caruso, S., et al. (2016) · FEBS Letters · doi:10.1002/1873-3468.12258 · Cited by 23
Theodore‐Oklota, C., Humphrey, L., Wiesner, C., Schnetzler, G., Hudgens, S. A., & Campbell, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s108489 · Cited by 23
Pharmacological Properties of Faster-Acting Insulin Aspart
Biester, T., Kordonouri, O., & Danne, T. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0931-y · Cited by 23
Shi, G. H., Connor, R., Collins, D. S., & Kang, D. W. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-020-01880-0 · Cited by 23
Shapiro, M. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1379738 · Cited by 22
Yadav, P., McLeod, V. M., Nowell, C. J., FitzGerald, L. I., Johnston, A. P. R., Kaminskas, L. M., & Trevaskis, N. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.031 · Cited by 22
Fine-Tuned Gene Expression Elements from Hybrid Promoter Libraries in Pichia pastoris
Lai, J., Song, L., Zhou, Y., Zong, H., Zhuge, B., & Lu, X. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00534 · Cited by 21
Kang, D. W., Bittner, B., Sugarman, B. J., Zepeda, M. L., & Printz, M. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254765 · Cited by 21
Li, H., Yang, J., Chen, Y., Guan, L., Du, L., Guo, Y., Wang, W., Wang, L., Li, H., Jiang, C., et al. (2014) · Protein Expression and Purification · doi:10.1016/j.pep.2014.03.007 · Cited by 21
Constitutive expression of recombinant human hyaluronidase PH20 by Pichia pastoris
Chen, K., Sabrina, S., El-Safory, N. S., Lee, G.-C., & Lee, C. (2016) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2016.06.007 · Cited by 21
Dang, X., Shih, H., Sharma, R. K., Angwin-Kaerner, D. T., Lin, K., Kapur, S., Thyagarajapuram, N. R., Shi, G. H., & Collins, D. S. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03683-5 · Cited by 20
Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance
Ding, X., Liang, Y., Zhou, S., Wu, Y., Sałata, P., Mikolajczk-Martinez, A., Khosrawipour, V., & Zhang, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113786 · Cited by 20
Sekhon, B. S. (2012) · Cited by 19
Robertis, M. D., Pasquet, L., Loiacono, L., Bellard, E., Messina, L., Vaccaro, S., Pasquale, R. D., Fazio, V. M., Rols, M., Teissié, J., et al. (2018) · Cancers · doi:10.3390/cancers10110405 · Cited by 20
Dimou, M., Iliakis, T., Maltezas, D., Bitsani, A., Kalyva, S., Koudouna, A., Kotsanti, S., Petsa, P., Papaioannou, P., Kyrtsonis, M., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12712 · Cited by 20
Lyophilization of High-Concentration Protein Formulations
Garidel, P., & Presser, I. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-8928-7_12 · Cited by 19
New insulins and insulin therapy
Danne, T., & Bolinder, J. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02576.x · Cited by 19
An industry perspective on hyaluronidase co-formulated biopharmaceutics
Guo, J., Weng, J., Zhou, F., & Gu, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.069 · Cited by 18
Comparing Subcutaneous Fluid Infusion with Intravenous Fluid Infusion in Children
Kuensting, L. L. (2012) · Journal of Emergency Nursing · doi:10.1016/j.jen.2012.04.017 · Cited by 18
Shell‐Crosslinked Hyaluronic Acid Nanogels for Live Monitoring of Hyaluronidase Activity In Vivo
Kim, J., Chong, Y., & Mok, H. (2014) · Macromolecular Bioscience · doi:10.1002/mabi.201300511 · Cited by 17
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs
Launay‐Vacher, V. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2289-4 · Cited by 17
Dychter, S. S., Ebel, D. L., Mead, T. R., & Yocum, R. C. (2009) · Current Therapeutic Research · doi:10.1016/j.curtheres.2009.12.005 · Cited by 17
Anti-CD20 Monoclonal Antibodies in Chronic Lymphocytic Leukemia: From Uncertainties to Promises
Bagacean, C., Zdrenghea, M., Tempescul, A., Cristea, V., & Renaudineau, Y. (2016) · Immunotherapy · doi:10.2217/imt-2015-0015 · Cited by 17
Hyaluronidase allergy mimicking orbital cellulitis
Raichura, N. D., Alam, M. S., Jaichandran, V., Mistry, S., & Mukherjee, B. (2017) · Orbit · doi:10.1080/01676830.2017.1383465 · Cited by 17
Sunstrom, N., & Sunstrum, F. N. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00479-y · Cited by 16
Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials
Mayasin, Y. P., Osinnikova, M. N., Kharisova, C. B., Kitaeva, K. V., Filin, I. Y., Gorodilova, A. V., Kutovoi, G. I., Solovyeva, V. V., Golubev, A. I., & Rizvanov, A. A. (2024) · Cells · doi:10.3390/cells13221917 · Cited by 16
Möller, C., Clark, E. A., Safavi-Hemami, H., DeCaprio, A. P., & Marí, F. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.05.002 · Cited by 16
Vũ, H. T., Peeters, E., Hofkens, K., Vandemeulebroecke, K., T’Sas, S., Martin, C., Ballet, S., Hoogenboom, R., Goossens, S., Lammens, T., et al. (2025) · Biomaterials Science · doi:10.1039/d5bm00138b · Cited by 15
Garg, S. K., Buse, J. B., Skyler, J. S., Vaughn, D. E., & Muchmore, D. B. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12315 · Cited by 15
Active Expression of Human Hyaluronidase PH20 and Characterization of Its Hydrolysis Pattern
Pang, B., He, J., Zhang, W., Huang, H., Wang, Y., Wang, M., Du, G., & Kang, Z. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.885888 · Cited by 15
A Systematic Data Review of the Cost of Rehydration Therapy
Pershad, J. (2010) · Applied Health Economics and Health Policy · doi:10.2165/11534500-000000000-00000 · Cited by 15
Angelotti, F., Capecchi, R., Giannini, D., Mazzarella, O., Rocchi, V., & Migliorini, P. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00633-4 · Cited by 15
Monahan, D. S., Almas, T., Wyile, R., Cheema, F. H., Duffy, G. P., & Hameed, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00885-3 · Cited by 15
Role of hyaluronidase as an adjuvant in local anesthesia for cataract surgery
Mohankumar, A., & Rajan, M. (2023) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2515_22 · Cited by 14
Knight, E., Carne, E. M., Novak, B., El‐Shanawany, T., Williams, P. E., Pickersgill, T. P., & Jolles, S. R. A. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.076828 · Cited by 14
Lou, H., Berkland, C. J., & Hageman, M. J. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120824 · Cited by 14
Kinetic investigation of recombinant human hyaluronidase PH20 on hyaluronic acid
Fang, S., Hays, A. A., & LaBarre, M. J. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.04.008 · Cited by 14
Jung, Y., Jung, M., Park, J., Jung, G. C., Hong, Y. S., Yeom, C. H., & Lee, S. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2010.06.003 · Cited by 14
Monoclonal Antibodies: From Structure to Therapeutic Application
Davis, J. D., Deng, R., Boswell, C. A., Zhang, Y., Li, J., Fielder, P. J., Joshi, A., & Kenkare-Mitra, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_7 · Cited by 14
Ho, M. J., Lee, D. R., Im, S. H., Yoon, J. A., Shin, C. Y., Kim, H. J., Jang, S. W., Choi, Y. W., Han, Y. T., & Kang, M. J. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.024 · Cited by 14
Routes of Delivery for Biological Drug Products
Irvine, D. J., Su, X., & Kwong, B. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse521 · Cited by 15
Rituximab by subcutaneous route
Solal-Celigny, P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1024651 · Cited by 13
Customer-centric product presentations for monoclonal antibodies
Bittner, B. (2023) · AAPS Open · doi:10.1186/s41120-022-00069-y · Cited by 12
New Frontiers in Subcutaneous Immunoglobulin Treatment
Jolles, S. R. A., Stein, M. R., Longhurst, H. J., Borte, M., Ritchie, B. C., Sturzenegger, M., & Berger, M. (2011) · Biologics in Therapy · doi:10.1007/s13554-011-0009-3 · Cited by 13
Rosengren, S., Souratha, J., Conway, D., Muchmore, D. B., & Sugarman, B. J. (2018) · BioDrugs · doi:10.1007/s40259-018-0260-y · Cited by 13
Connor, R., Clift, R., & Kang, D. W. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2252999 · Cited by 12
Hill, S. L., & Davies, A. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0574 · Cited by 12
Zambetti, M., Montemurro, F., Morandi, P., Zamagni, C., Brandes, A. A., Bisagni, G., Cagossi, K., Bengala, C., Gori, S., Iannacone, C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.034 · Cited by 12
PH20 is not expressed in murine CNS and oligodendrocyte precursor cells
Marella, M., Ouyang, J., Zombeck, J. A., Zhao, C., Huang, L., Connor, R., Phan, K. B., Jorge, M. C., Printz, M. A., Paladini, R. D., et al. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.393 · Cited by 12
Self-citationYelvington, B. J. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.5.7 · Cited by 12
Connor, R., Taverna, D. M., Thrall, K. D., LaBarre, M. J., & Kang, D. W. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106936 · Cited by 12
Eldridge, D. L. (2010) · Pediatric Emergency Care · doi:10.1097/pec.0b013e3181e5c00e · Cited by 12
Printz, M. A., Sugarman, B. J., Paladini, R. D., Jorge, M. C., Wang, Y., Kang, D. W., Maneval, D. C., & LaBarre, M. J. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00757-3 · Cited by 13
Li, Z., Follman, K., Freshwater, E., Engler, F. A., & Yel, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109331 · Cited by 11
Fang, S., Lollo, C. P., Derunes, C., & LaBarre, M. J. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.10.003 · Cited by 11
Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective
Carlson, J., Cox, K., Bedwell, K., & Ku, M. (2015) · International Journal of Nursing Practice · doi:10.1111/ijn.12413 · Cited by 11
Dimou, M., Speletas, M. G., Milito, C., Pyzik, A., Huscher, D., Kamieniak, M. M., Pittrow, D., & Borte, M. (2023) · Cancers · doi:10.3390/cancers15184524 · Cited by 10
Si, T., Ma, X., Zhu, W., & Zhou, Y. (2023) · Hematology · doi:10.1080/16078454.2023.2284047 · Cited by 10
Prospective Use of Brown Spider Venom Toxins as Therapeutic and Biotechnological Inputs
Gremski, L. H., Matsubara, F. H., Polli, N. L. C., Antunes, B. C., Schluga, P. H. D. C., da Justa, H. C., Minozzo, J. C., Wille, A. C. M., Senff‐Ribeiro, A., & Veiga, S. S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.706704 · Cited by 10
Continuous subcutaneous infusions and syringe drivers
Dickman, A. R., & Schneider, J. (2016) · doi:10.1093/med/9780198733720.003.0001 · Cited by 10
New Insulins and Insulin Therapy
Danne, T., & Bolinder, J. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.1505 · Cited by 11
Rathore, A. S., Metya, S., Sharma, R., & Nitika, N. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115812 · Cited by 11
Role of nanotechnology in the prolonged release of drugs by the subcutaneous route
Rama, B., & Ribeiro, A. J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2214362 · Cited by 9
Allmendinger, A. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03037-5 · Cited by 12
MacLean, C. M., Godsafe, Z., Forte, P., & Larsen, F. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1008 · Cited by 9
Subcutaneous immunoglobulin: facilitated infusion and advances in administration
Wasserman, R. L. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12519 · Cited by 9
Stability, Formulation, and Delivery of Biopharmaceuticals
Mahler, H., & Allmendinger, A. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch14 · Cited by 9
Wang, Y., Ji, P., Hariharan, S., Wang, J., Okusanya, Ó. O., Abuasal, B., Zhu, H., Madabushi, R., Huang, S. M., & Zineh, I. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3178 · Cited by 8
Kang, D. W., Connor, R., Nekoroski, T., Bitsura, J. A. M., Kindig, S. K., Knowles, S. P., & LaBarre, M. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01883-z · Cited by 9
Dorati, R., Cosco, D., Battaglia, L., Cirri, M., Conti, B., Borghi, T., Gabriele, M., Bruno, G. M., Rocco, P., Selmin, F., et al. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104441 · Cited by 8
Metadata
- Authors
- Frost, G. I.
- Affiliations
- Halozyme Therapeutics (United States) (US)
- Corresponding author
- Frost, Gregory I
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2007-07
- Volume
- 4
- Issue
- 4
- Pages
- 427-440
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2158548553
- Cited by
- 323
- References
- 66
- Citations by year
- 2026: 25 · 2025: 18 · 2024: 16 · 2023: 23 · 2022: 15 · 2021: 27 · 2020: 18 · 2019: 8 · 2018: 27 · 2017: 18 · 2016: 19 · 2015: 17 · 2014: 28 · 2013: 12 · 2012: 23
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Delivery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Keywords
- recombinant human hyaluronidase, rHuPH20, subcutaneous drug delivery, extracellular matrix, hyaluronic acid, subcutaneous tissue, injection volume, bioavailability, hyaluronidase, glycosaminoglycans, collagen, pharmacokinetics
- MeSH terms
- Amino Acid Sequence, Animals, Extracellular Matrix, Humans, Hyaluronoglucosaminidase, Injections, Subcutaneous, Molecular Sequence Data, Recombinant Proteins, Solubility, Protein Engineering, Cell Adhesion Molecules, Dermis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
